INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is a source of significant morbidity and mortality worldwide.
Risk factors include human papillomavirus (HPV) status and tobacco/alcohol use (1, 2) . Current staging and clinical management of HNSCC patients are based on anatomic location, size, and metastatic spread (3) . If patients undergo surgical excision without adjuvant therapy, management decisions are guided by lymph node invasion or the presence/absence of bone invasion (4) . Patients with locally advanced disease are treated aggressively with multimodal therapy including chemotherapy and radiotherapy along with surgical resection (5) .
Human papillomavirus is increasingly responsible for the growing incidence of oropharyngeal squamous cell carcinoma, representing 30% of HNSCC tumors (6) . Human papillomavirus-positive tumor status is usually associated with better response to therapy and survival, and is currently the strongest prognostic factor for these patients (7) . For HPV-negative tumors, no prognostic assays are widely accepted (4) . We designed this project based on the findings of our previous work (8) querying the Cancer Genomic Atlas (7) , which contains data on the largest collection of HNSCC tumor specimens. In this work (8) we found that among patients with HPVnegative tumors, reduced survival outcomes associated with tumor protein 53 (TP53) mutation only occur in combination with loss of chromosome 3p. This results in reduction of median survival from 5 years for TP53 mutation to only 1.7 years for "double-hit" mutations (TP53 and 3p) (8) . Beyond genetic mutations, the reasons for poor prognoses are still unclear. Current hypotheses focus on decreased radiosensitivity of double-hit tumors and the effects of infiltrating host immune cells (9) . Indeed, it has been shown that HNSCC tumors inhibit natural killer cells, T cells, and antigen-presenting cells, while recruiting regulatory T cells and tumor-associated macrophages (TAMs) (6) . The TAM burden has been shown to be a predictor of lymph node involvement and metastasis, and hence tumor aggressiveness (10) , and TAMs are known to secrete matrix metalloproteinases, which promote angiogenesis and tumor progression (11) .
To evaluate the role of TAMs in tumors with either TP53 mutation alone (single hit) or TP53 mutation combined with 3p deletion (double hit), we identified human HNSCC cell lines (Cal 27, SCC25, SCC15, and SCC4) from the American Type Culture Collection that have differential TP53 status and fragile histidine triad protein (FHIT) copy number as classified by the Cancer Cell Line Encyclopedia. The FHIT, located at position 3p14.2, is the gene locus most highly correlated with the 3p deletion in our Cancer Genomic Atlas analysis. The FHIT is a tumor suppressor gene that has been reported as frequently inactivated in HNSCC cell lines (12) . Decreased FHIT expression has been shown to correlate with worse survival in patients with tongue cancer (13) . In the 3p region, we found that the copy number variation for FHIT correlates best with 3p deletion status. The FHIT has been shown to be a tumor suppressor (14) , and FHIT-deficient mice show both increased incidence of spontaneous tumor formation as well as increased tumor formation in response to carcinogens (15) . Because previous in vivo ratiometric cell penetrating peptide experiments have shown that Cal27 xenografts have higher matrix metalloproteinases activity than SCC4 xenografts (13), we expect higher TAM accumulation in double-hit Cal27 compared with the single-hit SCC4 xenografts.
Clinically, invasive biopsy is the gold standard for diagnosis and genomic analysis of HNSCC, but there are several disadvantages of biopsying friable tumor tissue adjacent to vital structures in the head and neck, which include bleeding, damage to nerves/airway/vessels, and tumor cell deposition along the biopsy tract (16) . Previous work has validated the use of novel fluorine-19 ( 19 F) MRI probe technologies for macrophage tracking in preclinical studies (17) (18) (19) . In this approach, perfluorocarbon (PFC) nanoemulsion is injected intravenously, and the emulsion droplets are scavenged in situ by cells of the reticuloendothelial system, particularly circulating monocytes, macrophages, neutrophils, and dendritic cells (20) . These labeled cells can home to inflammatory foci and can be imaged by 19 F MRI with no endogenous background signal. Perfluorocarbon-labeled macrophages dominate MRIvisible 19 F "hot spots," and there is a linear correlation between 19 F signal and macrophage burden that can be quantitated directly from the in vivo images (18, 21) . Our aim is to evaluate this new imaging technology to noninvasively differentiate between double and single-hit tumors in a rodent model of head and neck tumor xenografts. Our results suggest that in situ PFC macrophage labeling and MRI is an effective, noninvasive tool for assaying TAM burden and may be predictive of treatment outcomes and the appropriateness of neoadjuvant treatments.
METHODS

Head and Neck Squamous Cell Carcinoma Cell Lines
Human tongue squamous cell carcinoma cell lines (Cal27 & SCC4) from American Type Culture Collection were used. The SCC4 cell line contained a missense TP53 mutation, and the Cal27 cell line contained both FHIT deletion and missense TP53 mutations (4) . In detail, this previous work demonstrated homozygous loss of FHIT (FHIT À/À ) for Cal-27 and FHIT heterozygosity (FHIT þ/-) for SCC-4. The TP53 gene was mutated in both cell lines; SCC-4 contains a missense mutation (G!A) on nucleotide 7578479 of chromosome 17p, and CAL-27 contains a missense mutation (T!A) on nucleotide 7578271. 21 F atoms) was injected intravenously via the lateral tail vein. For histology purposes, one animal in each group received a fluorescent version of the nanoemulsion (VS-1000H-DM-Red, Celsense Inc) containing a bright fluorophore bound to the PFC droplet, with emission/excitation wavelengths equal to 596/615 nm.
Mouse Model of HNSCC
In Vivo MRI and Quantification of 19 
F Signal
Mice were subjected to longitudinal MRI on days 2 and 10 after the PFC injection. The MRI data were acquired using an 11.7 T Bruker BioSpec preclinical scanner (Bruker, Billerica, MA) with a dual-tuned 1 H/ 19 F birdcage volume coil (Bruker). During the MRI, animals were anesthetized with 2% isoflurane in air, and their core temperature was maintained at 37 C using a heated pad. Reference capillaries with diluted PFC nanoemulsion (5% v/v) in 1% agarose were placed above the animal's torso in the image field of view. 19 F images were manually thresholded for visualization purposes to mask noise, and rendered in "red-hot" pseudo-color scale using Fiji software (24) , whereas the 1 H image remained in gray scale.
Histology and Immunofluorescence
After in vivo MRI experiments, tumors and lymph nodes were excised and kept in OCT medium (VWR, Radnor, PA, USA) for histology cryosectioning to evaluate immune cell recruitment. Frozen sections were dried in the dark for 20 min at room temperature, fixed in 4% paraformaldehyde (Affimetrix, Santa Clara, CA, USA), and then incubated with 2.5% bovine serum albumin in phosphate-buffered saline at room temperature for 15 min. Excess blocking reagent was discarded and the slides were incubated overnight in the dark at 4 C with a rabbit antimannose receptor 
Statistics
All measurements are presented as mean 6 standard error. A two-tailed t-test with unequal variances was performed to compare groups. The number of macrophages per tumor were correlated with total 19 F signal per tumor using a Pearson's correlation coefficient test. P values less than 0.05 were considered statistically significant.
RESULTS
In Vivo 19 F MRI Shows Macrophage Burden in the Tumor
In vivo PFC labeling and subsequent 1 H/ 19 F MRI revealed several fluorine hot spots located in the abdomen of the mice. The hot spots are displayed in the periphery of the tumors and in the adjacent lymph nodes (Fig. 1) . Visually, there are more hot spots associated with the Cal27 (double hit) tumors (Figs. 1a and 1c) versus the SCC4 tumors (single hit) (Figs. 1b and 1d) .
Quantitatively, ROI analyses reveal that the total number of 19 F atoms within the double-hit tumors is twice higher than the SCC4 single-hit tumors 2 days after PFC delivery ( Fig. 2a, P ¼ 0.0034) . The difference between the double and single-hit tumors remains significant at day 10 despite a mild decrease in overall signal over the course of 8 days (P ¼ 0.0063), showing that the imaging time window after agent injection is flexible. The number of macrophages per tumor moderately correlated to the fluorine signal (Pearson's r ¼ 0.63; Fig. 2c ). These quantitative differences support our hypothesis of increased TAM burden in the double-hit versus single-hit tumors. We also note that proximal lymph nodes (Figs. 1e and 1f, F atom count in the draining lymph nodes showing minor signal decrease for Cal27 tumors at day 10 compared with day 2, but no difference between the two groups at day 2; these differences were not significant (P > 0.05). Overall, signal in the lymph nodes is lower than in the periphery of the corresponding tumors by a factor of approximately 10. c: Plot showing moderate correlation (r ¼ 0.63) between number of fluorine atoms per tumor and macrophage infiltration (n ¼ 108; high power fields, HPF). F signal within the lymph nodes for both double and single-hit groups are lower than the corresponding tumors by a factor of approximately 10. At the experimental endpoints, all animals were sacrificed, and the tumors and lymph nodes were excised and cryopreserved for histology.
Ex Vivo Analyses
Hematoxylin-eosin (H&E) and immunofluorescence staining was performed on cryosectioned tumors and lymph nodes after completion of the MRI experiments (Figs. 3-5 ). Coregistration of cell nuclei (Hoechst 33342) and macrophage mannose receptor (green) stains enabled qualitative visual assessment of macrophage burden in slide micrographs. The slides reveal the presence of fluorescent green signal in the periphery of both Cal27 double-hit and SCC4 single-hit tumors, thus signifying the presence of TAMs within tumors (Fig. 4) , consistent with the 19 F/ 1 H MRI observations. The macrophage burden visually appears considerably higher for the Cal27 double-hit tumors (Fig.  4b) . Importantly, the dual-mode MRI-fluorescent PFC agent tends to colocalize intracellularly with the green fluorescence-depicting TAMs, consistent with macrophageassociated MRI hot spots (Fig. 4c) . As expected, similar fluorescence signals are observed in the regional draining lymph nodes (Fig. 5b) confirming the local accumulation of fluorine-containing macrophages, compared with a control lymph node showing minimal macrophage presence and no fluorine signal (Fig. 5c) .
DISCUSSION
To summarize, we show that PFC nanoemulsion and subsequent 1 H/ 19 F MRI allows for quantitative assessment of macrophage burden in tumors and adjacent lymph nodes in vivo. This imaging modality enables discrimination between double and single-hit head and neck cancer xenografts based on differential TAM accumulation at the tumor periphery. These findings are in concordance with histopathologic observations. The TAMs have been shown to accumulate at the tumor site and can be detected in vivo using in situ labeling techniques and MRI (25) .
Macrophages play a multidimensional role in cancer. The TAMs serve several pro-tumoral functions including the expression of growth, angiogenesis, and lymphangiogenesis factors. Moreover, TAMs release matrix proteases, leading to the suppression of adaptive responses (26, 27) . Considering this, the 19 F hot spots possibly represent the colonizing front of the tumor. The M1 macrophage subtype demonstrates high capacity to present antigens and activate polarized type I T-cell responses, resulting in cytotoxicity toward tumor cells. In contrast, M2 macrophages have poor antigen-presenting capacity, suppress inflammatory responses and Th1 adaptive immunity, and thus contribute in hijacking the local immune system away from antitumor function (28) . Tissue-resident macrophage number may be amplified through the recruitment and differentiation of circulating monocytes in the context of inflammation/tumor expansion (29) . Many growth and differentiation factors like M-CSF, PGE2, IL-6, and IL-10 expressed in the tumor microenvironment have the potential to promote differentiation and polarization of recruited monocytes into TAMs of the M2 subtype (30) . The TAMs also exert immunosuppressive activity by releasing chemokines that preferentially attract T-cell subsets devoid of cytotoxic function and thus facilitate tumor progression and metastatic invasion (5) . In situ labeling of TAMs with PFC does not permit M1/M2 phenotype discrimination.
Our results show increased accumulation of TAMs within the Cal27 double-hit tumors compared with the SCC4 single-hit tumors, thus confirming previous work that higher frequency of infiltrating TAMs have been associated with poor prognosis in many human tumors, particularly lymphoma, liver, and breast cancers (26, (31) (32) (33) . These preliminary preclinical observations could potentially have significant clinical relevance. Previous work have shown double-hit HNSCC to be less radiosensitive compared with single-hit tumors; the increased TAM accumulation in double-hit tumors could partially explain the observed aggressiveness (13) . Patients with double-hit/more aggressive tumor genotype would not benefit from radiotherapy alone; thus, different treatment options would be preferred that lead to increased survival, such as conjunction of radiotherapy with chemotherapy or inhibitors of the radioresistance pathway (34, 35) . Conversely, lower-grade single-hit tumor patients could be steered toward radiotherapy and/or surgical resection (35, 36) .
In vivo 19 F MRI also revealed high signal in local lymph nodes adjacent to both double and single-hit tumors. Overall, signals in the lymph nodes were 10 times lower than in the tumors. Histopathologic analyses further confirmed the presence of fluorine-labeled macrophages within these lymph nodes, compared with control lymph nodes from na€ ıve mice that showed minimal macrophage presence. In situ PFC cell labeling is expected to label only a small portion of macrophages. Go et al. (5) reported similar results for gastric cancer, describing immune cell accumulation in the lymphatic vessels of metastatic lymph nodes. They hypothesized that TAMs induce lymphangiogenesis and enhance lymphatic spreading of cancer by secreting vascular endothelial growth factor (5). They also noted that the number of intranodal immune cells in nonmetastatic nodes was higher in regions nearest to primary tumor, suggesting migration of macrophages from primary tumor to augment intranodal lymphangiogenesis (5) . In addition, the chemokines produced by TAMs in the tumor may reach the draining lymph nodes; thus, the tumor may thereby change the microenvironment of the surrounding regional lymph nodes before colonization of tumor cells. Others have shown that the density of M2 macrophages in regional lymph nodes is associated with lymphangiogenesis and occult nodal metastasis of pancreatic, oral squamous cell, and esophageal cancers (37, 38) . This would imply that the high 19 F signals we observe adjacent to the tumors are regional lymph nodes. Because these accumulation and potential spread of tumor, this information could be used for surgical planning to noninvasively map the regional draining lymph nodes associated with the tumor if these imaging techniques could be translated to humans, as discussed subsequently.
Overall, using nanoparticulate imaging probes, there are two hypotheses regarding the in vivo sites for TAM labeling (39); the first includes extravasation of circulating probe through the leaky tumoral vessels, which are then scavenged by local TAMs (40, 41) . The second hypothesis (42) suggests that reticuloendothelial cells, particularly monocytes, are labeled in the peripheral blood, which then migrate to the site of the cancer to serve a role of immune modulatory cells (29, 39) . We note that the plasma half-life of the PFC nanoemulsion formulation used is approximately 9.5 h in rodents (23); thus, there is ample time for either or both hypotheses to be relevant. Our view is that the actual in vivo site where labeling occurs is not central to the interpretation of the 19 F image data. The 19 F hot spots observed in this study were most likely dominated by labeled macrophages, but it is possible that other cells contributed to the observed 19 F signal. Very small numbers of B lymphocytes, neutrophils, and dendritic cells will take up PFC nanoemulsion (42, 43) . Measuring the average amount of PFC uptake per cell (macrophage) in situ is not feasible, unlike the case of ex vivo labeling experiments, in which apparent cell numbers at hot spots can be directly deduced from the in vivo imaging data after labeled cell infusion (44, 45) . However, it has been previously shown (18, 21) that the apparent number of 19 F atoms detected linearly correlates with the number of macrophages present and the inflammatory burden in vivo. Thus, relative TAM burden comparisons between tumors of different genotypes based on 19 F atom counts is plausible. Generally, MRI-detectable macrophages labeled with PFC can persist for long time periods; for example, a recent study using the same imaging agent in a murine model of inflammatory bowel disease (46) displayed PFC-labeled macrophages in the bowel wall for 110 days. Over time, eventually the PFC enters the RES system, particularly Kupffer cells of the liver, and PFC slowly clears the body via lung exhalation (47, 48) .
Our results suggest that there is a clinical rationale for potentially developing 19 F inflammation imaging for clinical diagnostic use. The PFC agent used in these studies was for preclinical use only, and there are currently no approved PFC agents for clinical inflammation imaging. However, we note that a PFC imaging agent with a similar composition to what has been used here has been used in a first-in-man clinical trial to detect immunotherapeutic dendritic cell vaccines injected into colorectal cancer patients (49) . However, in this study, a minuscule dose is delivered to the patient compared with what is needed for in situ cell labeling as described here; thus, the clinical development pathway is more complex. In addition, there are potential adverse effects of large PFC emulsion doses as observed in artificial blood substitute studies; side effects included headache, dizziness, nausea, vomiting, and back and chest pain, but these were mostly mild (79.8% of patients) (50); moreover, the severity of these effects may be dependent on the choice of molecular components for PFC nanoemulsion formulation.
The notion of performing 19 (45) . The sensitivity loss for the detection of labeled TAMs at lower clinical field strengths (3 T) compared with the preclinical MRI scanner (11.7 T) used in this study will depend on multiple factors such as field strength, coil configuration, voxel size and pulse sequence used, among other factors (52) . One of the rate-limiting factors in the clinical adoption of 19 F-based technologies is the current availability of 19 F-capable scanners in a hospital setting.
CONCLUSIONS
To conclude, we demonstrate the use of a novel noninvasive method to quantify apparent macrophage burden within head and neck tumors and local lymph nodes based on the use of PFC nanoemulsions and 19 F MRI detection. We show that this technology can discriminate between single and double-hit tumors with characteristic macrophage burden patterns, as well as sentinel lymph node involvement. Such an imaging tool would be very beneficial in a clinical setting to tailor personalized therapy without unnecessary biopsies.
